THX Pharma Société Anonyme (EPA:ALTHX)

France flag France · Delayed Price · Currency is EUR
3.370
-0.060 (-1.75%)
Feb 27, 2026, 5:35 PM CET
568.65%
Market Cap 46.49M
Revenue (ttm) 876.13K
Net Income (ttm) -2.94M
Shares Out 13.80M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 184,472
Average Volume 377,030
Open 3.460
Previous Close 3.430
Day's Range 3.330 - 3.540
52-Week Range 0.261 - 5.100
Beta 1.50
RSI 56.46
Earnings Date Apr 28, 2026

About EPA:ALTHX

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 10
Stock Exchange Euronext Paris
Ticker Symbol ALTHX
Full Company Profile

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.

Financial Statements

News

There is no news available yet.